Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1933 1
1945 1
1946 1
1948 3
1952 1
1961 2
1963 1
1964 2
1965 1
1968 3
1969 9
1970 3
1971 6
1972 10
1973 3
1974 4
1975 6
1976 10
1977 14
1978 5
1979 10
1980 8
1981 8
1982 8
1983 12
1984 9
1985 12
1986 18
1987 22
1988 17
1989 15
1990 21
1991 36
1992 34
1993 77
1994 58
1995 66
1996 102
1997 144
1998 257
1999 280
2000 358
2001 435
2002 455
2003 551
2004 603
2005 795
2006 694
2007 678
2008 777
2009 829
2010 772
2011 756
2012 718
2013 774
2014 772
2015 732
2016 744
2017 737
2018 735
2019 768
2020 926
2021 75
Text availability
Article attribute
Article type
Publication date

Search Results

14,720 results
Results by year
Filters applied: . Clear all
Page 1
Mycophenolate revisited.
van Gelder T, Hesselink DA. van Gelder T, et al. Transpl Int. 2015 May;28(5):508-15. doi: 10.1111/tri.12554. Transpl Int. 2015. PMID: 25758949 Free article. Review.
The patent of mycophenolate mofetil (MMF) has expired, and for enteric-coated mycophenolate sodium (EC-MPS), this will happen in 2017. ...Whether or not the development of donor-specific anti-HLA antibodies is related to drug exposure (mycophenolic acid conce …
The patent of mycophenolate mofetil (MMF) has expired, and for enteric-coated mycophenolate sodium (EC-MPS), this will happen …
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology.
Broen JCA, van Laar JM. Broen JCA, et al. Nat Rev Rheumatol. 2020 Mar;16(3):167-178. doi: 10.1038/s41584-020-0374-8. Epub 2020 Feb 13. Nat Rev Rheumatol. 2020. PMID: 32055040 Review.
Mycophenolate mofetil and azathioprine inhibit the purine pathway and subsequently diminish cell proliferation. ...In this Review, we discuss the historical perspective, pharmacodynamics, clinical indications and novel avenues for mycophenolate mofetil, azathioprine
Mycophenolate mofetil and azathioprine inhibit the purine pathway and subsequently diminish cell proliferation. ...In this Review, we
Clinical pharmacokinetics of mycophenolate mofetil.
Bullingham RE, Nicholls AJ, Kamm BR. Bullingham RE, et al. Clin Pharmacokinet. 1998 Jun;34(6):429-55. doi: 10.2165/00003088-199834060-00002. Clin Pharmacokinet. 1998. PMID: 9646007 Review.
Compared with mycophenolic acid, MPAG showed a roughly similar Cmax about 1 hour after mycophenolic acid Cmax, with a similar t1/2 and an AUC infinity about 5-fold larger than that for mycophenolic acid. ...Renal impairment had no major effect on the pharmaco …
Compared with mycophenolic acid, MPAG showed a roughly similar Cmax about 1 hour after mycophenolic acid Cmax, with a similar …
Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention.
Metz DK, Holford N, Kausman JY, Walker A, Cranswick N, Staatz CE, Barraclough KA, Ierino F. Metz DK, et al. Transplantation. 2019 Oct;103(10):2012-2030. doi: 10.1097/TP.0000000000002762. Transplantation. 2019. PMID: 31584924 Free PMC article. Review.
The immunosuppressive agent mycophenolate is used extensively in kidney transplantation, yet dosing strategy applied varies markedly from fixed dosing ("one-dose-fits-all"), to mycophenolic acid (MPA) trough concentration monitoring, to dose optimization to an MPA e …
The immunosuppressive agent mycophenolate is used extensively in kidney transplantation, yet dosing strategy applied varies markedly …
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. Ginzler EM, et al. N Engl J Med. 2005 Nov 24;353(21):2219-28. doi: 10.1056/NEJMoa043731. N Engl J Med. 2005. PMID: 16306519 Free article. Clinical Trial.
At 12 weeks, 56 patients receiving mycophenolate mofetil and 42 receiving cyclophosphamide had satisfactory early responses. ...Fewer severe infections and hospitalizations but more diarrhea occurred among those receiving mycophenolate. CONCLUSIONS: In this 24-week …
At 12 weeks, 56 patients receiving mycophenolate mofetil and 42 receiving cyclophosphamide had satisfactory early responses. ...Fewer …
Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
Staatz CE, Tett SE. Staatz CE, et al. Clin Pharmacokinet. 2007;46(1):13-58. doi: 10.2165/00003088-200746010-00002. Clin Pharmacokinet. 2007. PMID: 17201457 Review.
Mycophenolic acid (MPA) is the active drug moiety. Currently, two mycophenolate compounds are available, mycophenolate mofetil and enteric-coated (EC) mycophenolate sodium. ...Other co-medications can interfere with the absorption, enterohepatic recycl
Mycophenolic acid (MPA) is the active drug moiety. Currently, two mycophenolate compounds are available, mycophenolate
Treatment of presumptive primary immune-mediated thrombocytopenia with mycophenolate mofetil versus cyclosporine in dogs.
Cummings FO, Rizzo SA. Cummings FO, et al. J Small Anim Pract. 2017 Feb;58(2):96-102. doi: 10.1111/jsap.12621. J Small Anim Pract. 2017. PMID: 28160307
Variables were compared between dogs treated solely with mycophenolate mofetil and corticosteroids or cyclosporine and corticosteroids. ...Therapy with mycophenolate mofetil was less expensive than that with cyclosporine. ...
Variables were compared between dogs treated solely with mycophenolate mofetil and corticosteroids or cyclosporine and corticosteroid …
Immunosuppressants in Organ Transplantation.
Tönshoff B. Tönshoff B. Handb Exp Pharmacol. 2020;261:441-469. doi: 10.1007/164_2019_331. Handb Exp Pharmacol. 2020. PMID: 31820175
The major maintenance immunosuppressive agents currently used in various combination regimens are tacrolimus, cyclosporine, mycophenolate mofetil, azathioprine, everolimus, sirolimus, and glucocorticoids (steroids). ...
The major maintenance immunosuppressive agents currently used in various combination regimens are tacrolimus, cyclosporine, mycophenolate
Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea.
Arthur M, Fett NM, Latour E, Jacobe H, Kunzler E, Florez-Pollack S, Houser J, Sharma S, Prasad S, Femia A, Stern MJ, Pappas-Taffer LK, Gaffney R, Fernandez AP, Knabel D, Cardones AR, Leung N, Laumann A, Yu JM, Zhao J, Vleugels RA, Tkachenko E, Lo K. Arthur M, et al. JAMA Dermatol. 2020 May 1;156(5):521-528. doi: 10.1001/jamadermatol.2020.0035. JAMA Dermatol. 2020. PMID: 32236497
When this regimen is ineffective, not tolerated, or contraindicated, a trial of mycophenolate mofetil (MMF) or mycophenolic acid (MPA)-referred to herein as mycophenolate-is recommended; however, evidence to support this recommendation remains weak. ...MAIN O …
When this regimen is ineffective, not tolerated, or contraindicated, a trial of mycophenolate mofetil (MMF) or mycophenolic ac …
The role of mycophenolate in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis.
Koukoulaki M, Iatrou C. Koukoulaki M, et al. World J Nephrol. 2019 Aug 21;8(4):75-82. doi: 10.5527/wjn.v8.i4.75. World J Nephrol. 2019. PMID: 31523631 Free PMC article. Review.
Mycophenolic acid, the active metabolite for mycophenolate mofetil and mycophenolic sodium, is a strong, noncompetitive, reversible inhibitor of inosine monophosphate dehydrogenase, the key enzyme in de novo synthesis of guanosine nucleotides leading to selec
Mycophenolic acid, the active metabolite for mycophenolate mofetil and mycophenolic sodium, is a strong, noncompetitive
14,720 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page